Physician profile
Rachel Menges
NPI 1659856680
$1,617.64
in general payments reported to CMS, 2019-2025
20 companies · $20.57 in 2025
The $20.57 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $441 · 2022: $352 · 2023: $556 · 2024: $249 · 2025: $20.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $376.64 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $251.67 | 2021-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $242.86 | 2021-2024 | Farxiga, Airsupra |
| Pfizer INC. | $122.36 | 2023-2025 | |
| Astellas Pharma US INC | $114.43 | 2021-2023 | Veozah |
| Merck Sharp & Dohme LLC | $92.78 | 2021-2023 | Steglujan, Steglatro, Belsomra |
| Glaxosmithkline, LLC. | $89.16 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $57.05 | 2022 | |
| Abbott Laboratories | $43.46 | 2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $35.90 | 2022 | |
| Horizon Therapeutics Plc | $31.20 | 2021 | |
| Dexcom, INC. | $22.92 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $22.82 | 2024 | Nuedexta |
| Amarin Pharma, INC. | $21.11 | 2021 | |
| Esperion Therapeutics, INC. | $21.02 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $16.46 | 2023 | Onzetra Xsail, Contrave |
| Kowa Pharmaceuticals America, INC. | $15.02 | 2023 | Seglentis, Livalo |
| Amgen INC. | $15.00 | 2024 | Evenity, Prolia |
| Abbvie INC. | $13.37 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Menges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.